Patent application number | Description | Published |
20090238802 | Intraperitoneal Delivery Of Genetically Engineered Mesenchymal Stem Cells - A method of expressing at least one protein in an animal by intraperitoneal administration of mesenchymal stem cells genetically engineered with at least one polynucleotide encoding the at least one protein. The method may be employed in treating lysosomal storage disorders, such as Fabry Disease, or arthritic disorders, or hemophilia, for example. | 09-24-2009 |
20090257989 | Intraperitoneal Delivery Of Genetically Engineered Mesenchymal Stem Cells - A method of expressing at least one protein in an animal by intraperitoneal administration of mesenchymal stem cells genetically engineered with at least one polynucleotide encoding the at least one protein. The method may be employed in treating lysosomal storage disorders, such as Fabry Disease, or arthritic disorders, or hemophilia, for example. | 10-15-2009 |
20100119496 | ADIPOSE TISSUE DERIVED STROMAL CELLS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - The present invention relates to a treatment of neural injury and neurodegenerative diseases. Also included in the present invention is the use of adipose tissue derived stromal cells for the treatment of neural injury (stroke, traumatic brain injury, spinal cord injury) and neurodegeneration (i.e. Parkinson's disease). | 05-13-2010 |
20100255111 | Intraperitoneal Delivery of Genetically Engineered Mesenchymal Stem Cells - A method of expressing at least one protein in an animal by intraperitoneal administration of mesenchymal stem cells (or genetically engineered mesenchymal stem cells) with at least one polynucleotide encoding at least one protein. The method may be employed, for example, in treating lysosomal storage disorders, such as Fabry Disease, or arthritic disorders, or hemophilia, or diabetes. | 10-07-2010 |
20110027237 | Intraperitoneal Delivery of Genetically Engineered Mesenchymal Stem Cells - A method of expressing at least one protein in an animal by intraperitoneal administration of mesenchymal stem cells genetically engineered with at least one polynucleotide encoding the at least one protein. The method may be employed in treating lysosomal storage disorders, such as Fabry Disease, or arthritic disorders, or hemophilia, for example. | 02-03-2011 |
20110027241 | Intraperitoneal Delivery of Genetically Engineered Mesenchymal Stem Cells - A method of expressing at least one protein in an animal by intraperitoneal administration of mesenchymal stem cells genetically engineered with at least one polynucleotide encoding the at least one protein. The method may be employed in treating lysosomal storage disorders, such as Fabry Disease, or arthritic disorders, or hemophilia, for example. | 02-03-2011 |